Capricor Therapeutics, Inc. (CAPR) — 10-Q Filings

10-Q Filings (6)

• Capricor's Burn Rate Soars Amid Zero Revenue, R&D Costs Double — Nov 10, 2025 Risk: high
  CAPRICOR THERAPEUTICS, INC. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $74,873,032, a substantial rise f
• Capricor's Q2 Loss Widens Amid Revenue Dip, Capital Concerns — Aug 11, 2025 Risk: high
  CAPRICOR THERAPEUTICS, INC. reported a net loss of $10.5 million for the three months ended June 30, 2025, a significant increase from the net loss of $7.2 mill
• Capricor Therapeutics Q1 2025: Assets vs. Liabilities — May 14, 2025 Risk: medium
  Capricor Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported total assets of $45.58 million and total liabi
• Capricor Therapeutics Q3 2024 Financial Update — Nov 14, 2024 Risk: medium
  Capricor Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $40.33 million and total liabilities o
• Capricor Therapeutics Q2 2024 Financial Update — Aug 8, 2024 Risk: medium
  Capricor Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $31.98 million and total liabilities of $3.
• Capricor Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: medium
  CAPRICOR THERAPEUTICS, INC. (CAPR) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Capricor Therapeutics reported total assets of $31,148,320 and

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX